Cited 0 times in
Evaluation of rosuvastatin-induced QT prolongation risk using real-world data, in vitro cardiomyocyte studies, and mortality assessment
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 윤덕용 | - |
dc.date.accessioned | 2023-07-12T02:55:35Z | - |
dc.date.available | 2023-07-12T02:55:35Z | - |
dc.date.issued | 2023-05 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/195440 | - |
dc.description.abstract | Drug-induced QT prolongation is attributed to several mechanisms, including hERG channel blockage. However, the risks, mechanisms, and the effects of rosuvastatin-induced QT prolongation remain unclear. Therefore, this study assessed the risk of rosuvastatin-induced QT prolongation using (1) real-world data with two different settings, namely case-control and retrospective cohort study designs; (2) laboratory experiments using human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM); (3) nationwide claim data for mortality risk evaluation. Real-world data showed an association between QT prolongation and the use of rosuvastatin (OR [95% CI], 1.30 [1.21-1.39]) but not for atorvastatin (OR [95% CI], 0.98 [0.89-1.07]). Rosuvastatin also affected the sodium and calcium channel activities of cardiomyocytes in vitro. However, rosuvastatin exposure was not associated with a high risk of all-cause mortality (HR [95% CI], 0.95 [0.89-1.01]). Overall, these results suggest that rosuvastatin use increased the risk of QT prolongation in real-world settings, significantly affecting the action potential of hiPSC-CMs in laboratory settings. Long-term rosuvastatin treatment was not associated with mortality. In conclusion, while our study links rosuvastatin use to potential QT prolongation and possible influence on the action potential of hiPSC-CMs, long-term use does not show increased mortality, necessitating further research for conclusive real-world applications. © 2023. The Author(s). | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Nature Publishing Group | - |
dc.relation.isPartOf | SCIENTIFIC REPORTS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Action Potentials / physiology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Induced Pluripotent Stem Cells* | - |
dc.subject.MESH | Long QT Syndrome* / chemically induced | - |
dc.subject.MESH | Myocytes, Cardiac | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Rosuvastatin Calcium / adverse effects | - |
dc.title | Evaluation of rosuvastatin-induced QT prolongation risk using real-world data, in vitro cardiomyocyte studies, and mortality assessment | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Biomedical Systems Informatics (의생명시스템정보학교실) | - |
dc.contributor.googleauthor | Yeryung Koo | - |
dc.contributor.googleauthor | Sung-Ae Hyun | - |
dc.contributor.googleauthor | Byung Jin Choi | - |
dc.contributor.googleauthor | Yujeong Kim | - |
dc.contributor.googleauthor | Tae Young Kim | - |
dc.contributor.googleauthor | Hong-Seok Lim | - |
dc.contributor.googleauthor | Joung-Wook Seo | - |
dc.contributor.googleauthor | Dukyong Yoon | - |
dc.identifier.doi | 10.1038/s41598-023-35146-z | - |
dc.contributor.localId | A06062 | - |
dc.relation.journalcode | J02646 | - |
dc.identifier.eissn | 2045-2322 | - |
dc.identifier.pmid | 37208484 | - |
dc.contributor.alternativeName | Yoon, Dukyong | - |
dc.contributor.affiliatedAuthor | 윤덕용 | - |
dc.citation.volume | 13 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 8108 | - |
dc.identifier.bibliographicCitation | SCIENTIFIC REPORTS, Vol.13(1) : 8108, 2023-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.